Octagon Capital Advisors LP
About Octagon Capital Advisors LP’s 13F portfolio
Octagon Capital Advisors LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Octagon Capital Advisors LP reported $1.1B across 26 US-listed positions (). Its largest position is DIANTHUS THERAPEUTICS INC (DNTH) at 16% of the reported book, and its ten biggest holdings make up 80% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: DNTH DIANTHUS THERAPEUTICS INC | $84.83 +1.01% | 16% | 1.8M | $179.5M |
| 2 | NASDAQ: DFTX DEFINIUM THERAPEUTICS INC | — — | 13% | 3.0M | $138.8M |
| 3 | NASDAQ: ABVX ABIVAX SA | $80.65 −3.79% | 12% | 993K | $132.3M |
| 4 | NASDAQ: COGT COGENT BIOSCIENCES INC | $27.74 −0.25% | 8.3% | 2.4M | $90.9M |
| 5 | NASDAQ: ALMS ALUMIS INC | $4.33 −1.48% | 7.3% | 2.8M | $79.7M |
| 6 | NASDAQ: AVBP ARRIVENT BIOPHARMA INC | $11.26 +3.30% | 6.3% | 2.0M | $68.5M |
| 7 | NASDAQ: TSHA TAYSHA GENE THERAPIES INC | $3.77 −5.51% | 6.1% | 9.7M | $66.0M |
| 8 | NASDAQ: BIOA BIOAGE LABS INC | $4.71 −1.26% | 3.9% | 1.7M | $42.8M |
| 9 | NASDAQ: MIRM MIRUM PHARMACEUTICALS INC | $95.51 +3.27% | 3.6% | 339K | $39.7M |
| 10 | NASDAQ: KYMR KYMERA THERAPEUTICS INC | $119.39 −1.44% | 3.3% | 310K | $35.5M |
| 11 | NASDAQ: AKTS AKTIS ONCOLOGY INC | — — | 2.8% | 961K | $31.0M |
| 12 | NASDAQ: XENE XENON PHARMACEUTICALS INC | $37.56 −0.50% | 2.7% | 490K | $29.6M |
| 13 | NASDAQ: PALI PALISADE BIO INC | $0.93 −1.77% | 2.0% | 10.3M | $21.5M |
| 14 | NASDAQ: OCUL OCULAR THERAPEUTIX INC | $5.86 −1.35% | 1.9% | 2.1M | $20.4M |
| 15 | NASDAQ: IRON DISC MEDICINE INC | $76.11 −2.40% | 1.8% | 270K | $19.7M |
| 16 | NASDAQ: SMMT SUMMIT THERAPEUTICS INC | $10.57 +0.67% | 1.7% | 1.3M | $18.2M |
| 17 | NASDAQ: PHVS PHARVARIS N V | $31.66 +0.35% | 1.4% | 457K | $15.8M |
| 18 | NASDAQ: ANL ADLAI NORTYE LTD | $9.06 +3.66% | 1.0% | 935K | $10.7M |
| 19 | NASDAQ: DTIL PRECISION BIOSCIENCES INC | $6.91 −2.68% | 1.0% | 1.4M | $10.6M |
| 20 | NASDAQ: DBVT DBV TECHNOLOGIES S A | $9.42 −2.69% | 0.9% | 574K | $9.4M |
| 21 | NASDAQ: SNSE FAETH THERAPEUTICS INC | $25.96 −28.23% | 0.8% | 361K | $9.0M |
| 22 | NASDAQ: GYRE GYRE THERAPEUTICS INC | $4.52 +4.15% | 0.6% | 954K | $6.3M |
| 23 | NASDAQ: TRVI TREVI THERAPEUTICS INC | $13.72 +1.55% | 0.5% | 315K | $5.9M |
| 24 | NASDAQ: UNCY UNICYCIVE THERAPEUTICS INC | $3.53 −1.12% | 0.4% | 1.0M | $4.7M |
| 25 | NASDAQ: CNTX CONTEXT THERAPEUTICS INC | $0.17 +1.32% | 0.2% | 3.0M | $1.7M |
Showing 1–25 of 26 positions on this page reported in this 13F.
- Healthcare84%
- AddedDFTXDEFINIUM THERAPEUTICS INC+20.9%$138.8M
- AddedABVXABIVAX SA+46.7%$132.3M
- AddedTSHATAYSHA GENE THERAPIES INC+9.4%$66.0M
- NewSMMTSUMMIT THERAPEUTICS INC—$18.2M
- AddedPHVSPHARVARIS N V+177%$15.8M
- NewANLADLAI NORTYE LTD—$10.7M
- NewSNSEFAETH THERAPEUTICS INC—$9.0M
- NewGYREGYRE THERAPEUTICS INC—$6.3M
- ReducedDNTHDIANTHUS THERAPEUTICS INC−5.4%$179.5M
- ReducedKYMRKYMERA THERAPEUTICS INC−27.1%$35.5M
- ReducedOCULOCULAR THERAPEUTIX INC−34.5%$20.4M
- ReducedDTILPRECISION BIOSCIENCES INC−39.6%$10.6M
- ReducedTRVITREVI THERAPEUTICS INC−78.8%$5.9M
- ReducedCNTXCONTEXT THERAPEUTICS INC−41.9%$1.7M
- SoldEVMNEVOMMUNE INC−100%—
- SoldBBOTBRIDGEBIO ONCOLOGY THERAPEUT−100%—
- SoldTERNTERNS PHARMACEUTICALS INC−100%—
- SoldKALVKALVISTA PHARMACEUTICALS INC−100%—
Reading Octagon Capital Advisors LP’s 13F portfolio
Octagon Capital Advisors LP’s $1.1B 13F book is spread across 26 reported positions and is highly concentrated — its ten largest positions alone are 80% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are DNTH, DFTX, ABVX, COGT and ALMS, led by DIANTHUS THERAPEUTICS INC (DNTH) at 16% of the portfolio. The heaviest sector exposure is Healthcare (84%).
What Octagon Capital Advisors LP changed last quarter
Between 2026-03-31 and Q2 2026, Octagon Capital Advisors LP was a net seller: it opened 4 new positions and added to 4 more, while trimming 6 and closing 7 outright. Against a 26-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was DEFINIUM THERAPEUTICS INC (DFTX), and its biggest reduction was DIANTHUS THERAPEUTICS INC (DNTH).
What a 13F does and doesn’t reveal
A 13F captures only Octagon Capital Advisors LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Octagon Capital Advisors LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Octagon Capital Advisors LP's profile on this page is built directly from those filings.
How current is the 13F data on Octagon Capital Advisors LP's page?
It reflects Octagon Capital Advisors LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Octagon Capital Advisors LP files its next quarterly report, this page refreshes automatically.
Can I see Octagon Capital Advisors LP's complete list of holdings?
This page highlights Octagon Capital Advisors LP's largest positions rather than all 26 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Octagon Capital Advisors LP's filings.
Does a 13F show everything Octagon Capital Advisors LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Octagon Capital Advisors LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Octagon Capital Advisors LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

